Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

This is a Phase I safety study testing a new radioactive drug called [177Lu]Lu-DFC413 in patients with certain advanced solid tumors, including pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC) that have not responded to prior treatments. **You may be eligible if...** - You are 18 or older - You have advanced, unresectable, or metastatic pancreatic cancer OR non-small cell lung cancer without actionable gene mutations - Your cancer has progressed after standard chemotherapy or immunotherapy, or you were unable to receive those treatments - You are in adequate physical health for the study procedures **You may NOT be eligible if...** - You have received certain prior radioactive treatments - Your kidney, liver, or bone marrow function is too poor - You have active brain metastases or uncontrolled infection Talk to your doctor to see if this trial is right for you.